Find clinical trials for Kidney Disease in Rochester, MN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Kidney Disease trials near Rochester, MN, USA:
is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...
Phase 3
Rochester, Minnesota, United States and 17 other locations
To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)* To characterize the pharmacokinetic (PK) properties of RGLS...
Phase 1
Rochester, Minnesota, United States and 27 other locations
safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney...
Phase 1
Rochester, Minnesota, United States and 11 other locations
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney ...
Phase 3
Rochester, Minnesota, United States and 27 other locations
This study is an open-label, multi-center study evaluating the clinical utility of Renasight in the diagnosis and management of kidney disease...
Rochester, Minnesota, United States and 30 other locations
The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-...
Phase 3
Rochester, Minnesota, United States and 22 other locations
PLD (ADPLD) or associated with autosomal dominant polycystic kidney disease (ADPKD).In the Treatment Period of the trial, participa...
Phase 2, Phase 3
Rochester, Minnesota, United States and 10 other locations
or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems rel...
Phase 3
Rochester, Minnesota, United States and 547 other locations
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants w...
Phase 3
Rochester, Minnesota, United States and 55 other locations
(LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease...
Phase 3
Rochester, Minnesota, United States and 177 other locations
Clinical trials
Research sites
Resources
Legal